Almost 90% of American have used digital health tools, claims Rock Health
The survey found that...
According to a recent survey by Rock Health, 87% of respondents in the US have, at least once, used digital health tools in 2017.
The survey found that the figure rose by 7 percentage points from the previous year, as only 80% had used digital health tools in 2016.
The survey, the third annual report released from the firm, shows results from 4,000 individuals in the US.
The report found that the post popular of tools were health information, of which 79% of respondents had used, and provider reviews, which 58% of the survey had used.
24% of those questioned had used wearables and mobile tracking, with 19% having used video telemedicine.
“The good news for digital health innovators is consumers generally like using their products,”Megan Zweig, Rock Health’s Director of Research, informed HealthExec.
“People are largely satisfied with their telemedicine visits, and even report that wearables and other health tracking apps are helping them achieve their health goals.”
“Relationships really do matter in healthcare, and this is evident in how consumers interact with digital tools.”
“Consumers are much more likely to trust in provider data security and share their healthcare data with providers – especially compared to tech companies.”
“This means providers have substantial sway in terms of digital tool adoption – a prescription or recommendation from a care team member is going to carry a lot of weight with a patient.”
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”